Genomenon provides a comprehensive genomicsearch platform named Mastermind to identify and analyze genetic evidence found across the complete corpus of scientific articles. Powered by its proprietary Genomic Language Processing (GLP) algorithms and genomic literature database, Mastermind finds every published association across genes, variants, diseases, phenotypes, and therapies with a simple Google-like interface. The search results empower scientists and researchers at pharmaceutical companies, clinical labs, and universities across the globe to understand diseases at a molecular level. “We are revolutionizing the way genomic informationis searched, made available, and understood,” says Mike Klein, CEO of Genomenon.
Genomenon powers precision medicine for both clinical and pharmaceutical research.
![]()
We are revolutionizing the way genomic information is searched, made available, and understood
This can reduce variant interpretation time 5-fold and increase diagnostic yield by 10-12 percent, and assures repeatability in reporting genetic testing results. Thousands of doctors in over 100 countries use Mastermind to effectively diagnose cancer patients and babies born with rare diseases.
Pharmaceutical and biopharma companies look to understand the entire genetic landscape of a disease rather than case by case. To that end, Genomenon offers the Mastermind Genomic LandscapeTM, essentially a dataset with comprehensive genetic information backed by scientific evidence to drive successful precision medicine programs. Mastermind enables target identification and validation by providing the genetic drivers for a disease and pinpointing variants known to be pathogenic. The genomic landscape is also a powerful tool for identifying the genetic biomarkers needed to screen patients for clinical trial stratification.
Genomenon has been consistently recognized as an innovator since its inception. The company was recently named the 2020 Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan for delivering comprehensive genomics data interpretation, resulting in more accurate diagnoses.
Later this year, the company will be the first to deliver a comprehensive genomic landscape for ALS (Lou Gherig’s Disease) for researchers and pharmaceutical companies focused on the disease. With its comprehensive genomics data interpretation for precision medicine, Genomenon is poised to maintain a strategic role in evolving value-based healthcare landscape, improving patient outcomes.
Share this Article:
Tweet
|
Company
Genomenon
Headquarters
Ann Arbor, MI
Management
Mike Klein, CEO
Description
Genomenonis a genomic health IT company that connects genomics research to patient DNA to help diagnose and develop precision medicines for patients with rare genetic diseases and cancer. The company provides a comprehensive genomic search platform named Mastermind to identify and analyze genetic evidence found across the complete corpus of scientific articles. The search results empower scientists and researchers at pharmaceutical companies, clinical labs, and universities across the globe to understand diseases at a molecular level. Genomenon was recently named the 2020 Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan for delivering comprehensive genomics data interpretation, resulting in more accurate diagnoses